% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{z:120030,
      author       = {A. S. Öz$^*$ and G. Raddatz$^*$ and M. Rius Montraveta$^*$
                      and N. Blagitko-Dorfs and M. Lübbert and C. Maercker$^*$
                      and F. Lyko$^*$},
      title        = {{Q}uantitative determination of decitabine incorporation
                      into {DNA} and its effect on mutation rates in human cancer
                      cells.},
      journal      = {Nucleic acids symposium series},
      volume       = {42},
      number       = {19},
      issn         = {1362-4962},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press44364},
      reportid     = {DKFZ-2017-00618},
      pages        = {e152 - e152},
      year         = {2014},
      abstract     = {Decitabine (5-aza-2'-deoxycytidine) is a DNA
                      methyltransferase inhibitor and an archetypal epigenetic
                      drug for the therapy of myeloid leukemias. The mode of
                      action of decitabine strictly depends on the incorporation
                      of the drug into DNA. However, DNA incorporation and ensuing
                      genotoxic effects of decitabine have not yet been
                      investigated in human cancer cell lines or in models related
                      to the approved indication of the drug. Here we describe a
                      robust assay for the quantitative determination of
                      decitabine incorporation rates into DNA from human cancer
                      cells. Using a panel of human myeloid leukemia cell lines we
                      show appreciable amounts of decitabine incorporation that
                      closely correlated with cellular drug uptake. Decitabine
                      incorporation was also detectable in primary cells from
                      myeloid leukemia patients, indicating that the assay is
                      suitable for biomarker analyses to predict drug responses in
                      patients. Finally, we also used next-generation sequencing
                      to comprehensively analyze the effects of decitabine
                      incorporation on the DNA sequence level. Interestingly, this
                      approach failed to reveal significant changes in the rates
                      of point mutations and genome rearrangements in myeloid
                      leukemia cell lines. These results indicate that standard
                      rates of decitabine incorporation are not genotoxic in
                      myeloid leukemia cells.},
      keywords     = {Antimetabolites, Antineoplastic (NLM Chemicals) / DNA,
                      Neoplasm (NLM Chemicals) / decitabine (NLM Chemicals) /
                      Azacitidine (NLM Chemicals)},
      cin          = {A130 / W110},
      ddc          = {540},
      cid          = {I:(DE-He78)A130-20160331 / I:(DE-He78)W110-20160331},
      pnm          = {311 - Signalling pathways, cell and tumor biology
                      (POF3-311)},
      pid          = {G:(DE-HGF)POF3-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:25159616},
      pmc          = {pmc:PMC4231731},
      doi          = {10.1093/nar/gku775},
      url          = {https://inrepo02.dkfz.de/record/120030},
}